United Kingdom · Question · Written question
UIN 200017
Adrenoleukodystrophy and Thalassaemia: Gene Therapies
Introduced
18 September 2023
Last action
—
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
16 October 2023
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the withdrawal of Bluebird Bio from the (a) UK and (b) European market on access to gene therapy treatment for people with (i) beta thalassemi
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.